The nation of Zimbabwe has rejected a major American health deal worth $367m (272 million pounds) over five years over Washington's demand for confidential data.
The decision was revealed following a internal memorandum dated December was disclosed, which showed Head of State Emmerson Mnangagwa believed the agreement was "unbalanced".
An official spokesman has since stated that the US was demanding access to genetic material for research and commercial purposes while was not willing to guarantee the benefits from any future treatments.
"We must now begin the difficult and regrettable process of scaling back our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had furnished more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for more negotiations to find a deal suitable to both sides so the country's vital HIV programme can proceed.
Wider Background
This rejection follows a similar case in Kenya, where a high court suspended a related deal with the US following legal challenges were raised about the security of Kenyans' health data.
After resuming office last year, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump stated its spending was "inefficient" and his government was seeking direct bilateral deals to enhance openness and responsibility.
According to statements, 16 nations in Africa have to date signed these new agreements, representing over $18.3bn of fresh investment.
Specifics of the Declined Agreement
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration might have yielded significant advantages for the people of Zimbabwe, particularly the 1.2 million presently on HIV treatment via US-supported programmes," the Ambassador commented.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to provide its biological resources and data for a long time, without any equivalent guarantee of access to any scientific breakthroughs – like new medicines or tests – that might result from that shared data," Mangwana explained.
"Effectively, our country would supply the raw materials for scientific discovery without any certainty that the end products would be accessible to our people should a new pandemic arise."
National Interest and International Frameworks
Mangwana further said that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were upending structures already established through the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system designed to deal with future global health emergencies.
"This mechanism is intended to guarantee that when a country provides its information, the benefits – such as medicines and cures – are shared equitably, not monopolised solely by those with the capability to create them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We are open to continued discussions with our US partners on how subsequent collaboration could be designed in a way that respects the independence and dignity of both nations."
Medical Community Response
A leading public health body said it recognised the official position, but suggested that talks should continue since much of the country's Aids initiatives were funded by international support.
"Where specific concerns arise, such as those involving data governance or agreement terms, these can frequently be resolved via technical clarification and negotiated safeguards," the group added.
This impasse emphasises the complex debate between receiving crucial foreign assistance and protecting local interests in an increasingly interconnected world.